Navigation Links
Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
Date:12/4/2008

AMSTERDAM, December 4 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute GvHD occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with a mismatched transplant procedure.

Following scientific advice from the EMEA Kiadis Pharma is preparing to initiate a multi center multinational pivotal study starting recruitment early 2009. In this study the efficacy of ATIR(TM) will be investigated in patients diagnosed with AML, ALL or MDS eligible for an allogeneic bone marrow transplantation but for whom no matching donor is available.

"Bone marrow transplantations are often the only treatment option left for end-stage blood cancer patients. But too many patients simply do not find a suitable matched donor in time" says Dr. Denis-Claude Roy of the Maisonneuve-Rosemont Hospital in Montreal, the principal investigator on the study. "Our study shows a rapid immune reconstitution in transplanted patients provided with ATIR(TM) treated immune cells from mismatched donors. Without ATIR(TM) treatment this would not be possible because of the high risk of acute Graft versus Host Disease with mismatched donor immune cells. This is obviously a very hopeful development for a large patient group."

Dr. Manja Bouman, CEO of Kiadis Pharma, says "The results of this clinical trial are very encouraging and it is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe an
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
2. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
5. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
6. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
7. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
8. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
9. Isogen Launches Major New Facility to Address Global Biopharma Demand
10. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
11. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... ACUO TECHNOLOGIES, developers of h... data migration tools and services, is pleased to ...rk Office has approved a patent application for an...work." Acuo Technologies is pleased to add the U.S.... In general, the granted patent application broad...
(Date:11/25/2009)...5 Heska Corporation ( HS...iagnostic and specialty products to the veterinary...iagnostics Corporation for the supply of blood gas...inary market. ,, (Logo: http://www.newscom...a and Roche share the same passion for innovating ...
(Date:11/25/2009)...wswire/ -- BioTrends Research Group, Inc. released...eport, the first in a multi-phase syndicated marke... Ortho-Biotech,s Stelara, from product launch thro...ve of the report provides quantitative information...ormation from a subset of 20. The reports assess ...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 1FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 2FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 3FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 4Dr Ken Dychtwald to Discuss Looming Caregiver Crunch and the Importance of Proactive Long Term Care Planning 60239 1Dr Ken Dychtwald to Discuss Looming Caregiver Crunch and the Importance of Proactive Long Term Care Planning 60239 2Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 1Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 2Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 3Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 4Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 5Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 6
...y 21 Romark Laboratories, L.C., a,privately-owned...mpletion,of enrollment into its Phase II clinical ...oxanide in combination with standard of care thera...ype 1 who have previously,failed to respond to the...irin). The company expects to announce interim dat...
...rgentina, May 21 Today at the,World Congress of C...w,Perspectives in Atrial Fibrillation Management" ...ogy, St George,s University of London,highlighted ...cal trial,results, as the way forward in the futur...on form of cardiac arrhythmia., To view the Multi...
Other Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6
(Date:11/29/2009)..., SANTA CRUZ, CA--New connections begin to form b...earn a new task, according to a study published th...versity of California, Santa Cruz, the study invol...s that take place in the brain during motor learni...trained to reach through a slot to get a seed. The...
(Date:11/29/2009)...any doctors unaware the sleep disorder boosts urin...ov. 29 (HealthDay News) -- People who wake up duri...ame a urological problem. Sleep apnea, a breathing...A new study suggests that nighttime urination, or ...r for obstructive sleep apnea, a disorder in which...
(Date:11/28/2009)..., , CHICAGO, Nov. 28 Get...on practice in the clinical routine when Sieme...entific Assembly and Annual Meeting of the Radiolo...r 29 to December 3 at McCormick Place (Booth #825,.... With syngo. via , Siemens, new imaging s...
(Date:11/27/2009)..., , BEDFORD, Mass., Nov. 27 /PRNewswire-Fi...e "Company"), a supplier of precision technology p... that an annual meeting of the Company,s sharehold... The time and location of the meeting will be ann...e Company received a requisition notice from Steph...
(Date:11/27/2009)..., , SAN FRANCISCO, Nov. 27 /PRNewswire-First... announced that Blair Lambert, CFO/COO, will prese...will be held at the May Fair Hotel in London, Engl... GMT. ,, To listen to a live broadcast of The G...et, please log on to www.gymboree.com, click on "O...
Breaking Medicine News(10 mins):Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2
...Health Minister Dr Anbumani Ramadoss, in an attemp...ese Encephalitis has left for Beijing to approach ...able in a sizeable // quantity. The heavy toll of ...iled discussions with the Chinese minister for Nat...
...Doctors say they want to investigate the case of a...of the virus, reports BBC. // Two Sunday news...in London, was diagnosed as HIV-positive in 2002, ... tests. Stimpson did not take any medication for H...
...Study results showed that people who lived longer ... social position. The research study was carried o...d's School of Public Health who reported their fin...ildren’s with a score more than 130 are considered...
...John Cacioppo and researchers have found that the ...d it runs in to families making it a genetic chara...le should join a group which has more social chara...nd they found that loneliness is not related to he...
...A new study appearing in the November 1, 2005 issu...that a new gene profile may help in predicting how...nd to aggressive chemotherapy. // In many patie...nce of chemotherapy-resistant cancer cells, most p...
...In a breakthrough, which could eventually lead to ...he HIV virus, scientists from the US National Canc...ving in the human body to produce chemicals that b... bacteria. The researchers have successfully...
Other Medicine News:Health News:Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations 2Health News:British man 'Recovered from HIV' 2Health News:Genetic Profile To Predict Ovarian Cancer Prognosis 2Health News:Genetically modified bacteria to combat HIV 2
Maumenee tying forceps
Anis tying forceps
McPherson tying forceps
Harms-Tubingen Straight Tying Forceps
Medicine Products: